Breaking News Instant updates and real-time market news.

ADAP

Adaptimmune

$3.39

0.165 (5.12%)

08:31
05/31/19
05/31
08:31
05/31/19
08:31

Adaptimmune initiated with a Buy at Roth Capital

Roth Capital analyst Tony Butler initiated Adaptimmune with a Buy rating and $7 price target, stating that the company has a differentiated and highly optimized approach to developing T-cell receptors and has shown strong early-stage data in synovial sarcoma. He also thinks ADP-A2M4 could demonstrate promising data in esophageal cancer, Butler tells investors.

  • 31

    May

  • 04

    Jun

  • 17

    Jun

ADAP Adaptimmune
$3.39

0.165 (5.12%)

05/30/19
SBSH
05/30/19
INITIATION
Target $8
SBSH
Buy
Adaptimmune assumed with a Buy at Citi
Citi analyst Mohit Bansal assumed coverage Adaptimmune Therapeutics with a Buy rating and $8 price target. Under a prior analyst, Citi had a Buy rating on the shares with a $17 price target. The company needs efficacy data beyond sarcoma to boost investor confidence, Bansal tells investors in a research note.
05/24/19
PIPR
05/24/19
NO CHANGE
Target $11
PIPR
Overweight
Alpine Immune Sciences Kite pact termination 'a win,' says Piper Jaffray
Last week's new collaboration and license agreement between Alpine Immune Sciences (ALPN) with Adaptimmune (ADAP) essentially replaced the old deal between Kite Pharma and Gilead (GILD), termination of which was announced in a regulatory filing earlier today and is driving Alpine shares lower, Piper Jaffray analyst Edward Tenthoff tells investors in a research note to investors. Tenthoff says he sees this as a win for Alpine, who received $2M upfront and is eligible for an additional $288M in milestones, adding that he is a buyer of Alpine Immune Sciences on today's weakness ahead of ALPN-101 safety and biomarker data this quarter. Tenthoff maintains an Overweight rating and $11 price target on Alpine Immune Sciences shares.
05/15/19
PIPR
05/15/19
NO CHANGE
Target $11
PIPR
Overweight
Piper sees broad partnership potential for Alpine after Adaptimmune deal
After Alpine Immune Sciences (ALPN) announced a partnership with Adaptimmune (ADAP) to incorporate its novel Transmembrane and Secreted Immunomodulatory Proteins, or TIPs and SIPs, into CAR-T cells, Piper Jaffray analyst Edward Tenthoff said he sees Alpine having broad potential to partner its TIPs and SIPs for next generation cellular therapies. The analyst, who noted that Alpine is also advancing a platform of novel variant Ig domains, or "vIgDs," to augment T-cell activation, keeps an Overweight rating and $11 price target on Alpine shares.
05/07/19
RAJA
05/07/19
NO CHANGE
Target $6
RAJA
Outperform
Adaptimmune price target lowered to $6 from $16 at Raymond James
Raymond James analyst Reni Benjamin lowered his price target for Adaptimmune to $6 from $16, while reiterating an Outperform rating on the shares after the company presented Q1 financial results and provided a "major update" for the ongoing clinical programs. The analyst notes that preliminary results from synovial sarcoma patients treated at therapeutically relevant doses of ADP-A2M4 showed "promising results," and that the company plans to initiate a Phase 2 SPEARHEAD-1 study of ADP-A2M4 in synovial sarcoma patients in the second half of 2019 and to initiate two additional studies to evaluate efficacy and durability of ADP-A2M4 and ADP-A2M10 with radiation in several solid tumor indications. Outside of synovial sarcoma, all other indications showed promising but mixed results, he added.

TODAY'S FREE FLY STORIES

KRYS

Krystal Biotech

$29.28

0.28 (0.97%)

08:10
06/24/19
06/24
08:10
06/24/19
08:10
Hot Stocks
Krystal Biotech anticipates commencing Phase 3 KB103 trial before year-end »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$29.28

0.28 (0.97%)

08:09
06/24/19
06/24
08:09
06/24/19
08:09
Hot Stocks
Krystal Biotech says safety data shows KB103 was wll-tolerated »

Krystal Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$20.68

-0.135 (-0.65%)

, CVS

CVS Health

$53.68

-0.19 (-0.35%)

08:08
06/24/19
06/24
08:08
06/24/19
08:08
Hot Stocks
Tenet, Aetna announce multi-year agreement »

Tenet (THC) and Aetna, a…

THC

Tenet

$20.68

-0.135 (-0.65%)

CVS

CVS Health

$53.68

-0.19 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RST

Rosetta Stone

$23.23

0.09 (0.39%)

08:06
06/24/19
06/24
08:06
06/24/19
08:06
Conference/Events
Rosetta Stone management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

PHR

Phreesia

$0.00

(0.00%)

08:05
06/24/19
06/24
08:05
06/24/19
08:05
Syndicate
Phreesia files registration statement for IPO »

Phreesia announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRG

NRG Energy

$35.22

0.2 (0.57%)

08:04
06/24/19
06/24
08:04
06/24/19
08:04
Upgrade
NRG Energy rating change  »

NRG Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNW

Pinnacle West

$97.60

-0.97 (-0.98%)

08:04
06/24/19
06/24
08:04
06/24/19
08:04
Conference/Events
Pinnacle West management to meet with Wolfe Research »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

BDSI

BioDelivery Sciences

$4.41

-0.05 (-1.12%)

08:04
06/24/19
06/24
08:04
06/24/19
08:04
Hot Stocks
BioDelivery Sciences expands upon report from Pain Management Task Force »

BioDelivery Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHAS

PhaseBio

$12.52

0.54 (4.51%)

08:02
06/24/19
06/24
08:02
06/24/19
08:02
Conference/Events
PhaseBio management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

RBB

RBB Bancorp

$19.13

-0.45 (-2.30%)

08:02
06/24/19
06/24
08:02
06/24/19
08:02
Hot Stocks
RBB Bancorp announces 1M share repurchase program »

RBB Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPL

Texas Pacific Land Trust

$773.00

-21 (-2.64%)

08:02
06/24/19
06/24
08:02
06/24/19
08:02
Hot Stocks
Texas Pacific Land Trust to explore conversion to C-corporation »

Texas Pacific Land Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCL

Royal Caribbean

$114.85

-3.94 (-3.32%)

08:01
06/24/19
06/24
08:01
06/24/19
08:01
Hot Stocks
Royal Caribbean, ITM Group partner to form new destination company »

Royal Caribbean and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTYH

GTY Technology Holdings

$7.64

-0.26 (-3.29%)

08:01
06/24/19
06/24
08:01
06/24/19
08:01
Hot Stocks
GTY Technology Holdings announces cooperative contract with Texas DIR »

GTY Technology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$74.34

0.94 (1.28%)

07:59
06/24/19
06/24
07:59
06/24/19
07:59
Hot Stocks
Alnylam presents new ONPATTRO results at 2019 PNS meeting »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMSY

HMS Holdings

$31.86

-0.71 (-2.18%)

, UNH

UnitedHealth

$252.31

4.53 (1.83%)

07:57
06/24/19
06/24
07:57
06/24/19
07:57
Recommendations
HMS Holdings, UnitedHealth analyst commentary  »

HMS Holdings' recent…

HMSY

HMS Holdings

$31.86

-0.71 (-2.18%)

UNH

UnitedHealth

$252.31

4.53 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 18

    Jul

CZR

Caesars

$9.99

-0.05 (-0.50%)

, ERI

Eldorado Resorts

$51.22

-1.48 (-2.81%)

07:56
06/24/19
06/24
07:56
06/24/19
07:56
Hot Stocks
Caesars to adjourn Annual Meeting of shareholders »

Caesars Entertainment…

CZR

Caesars

$9.99

-0.05 (-0.50%)

ERI

Eldorado Resorts

$51.22

-1.48 (-2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 25

    Jun

TTPH

Tetraphase

$0.63

-0.02 (-3.10%)

07:56
06/24/19
06/24
07:56
06/24/19
07:56
Hot Stocks
Tetraphase presents new Xerava data at ASM »

Tetraphase announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNCE

Concert Pharmaceuticals

$10.90

-0.165 (-1.49%)

07:53
06/24/19
06/24
07:53
06/24/19
07:53
Initiation
Concert Pharmaceuticals initiated  »

SunTrust starts Concert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

WAB

Wabtec

$72.75

0.42 (0.58%)

07:52
06/24/19
06/24
07:52
06/24/19
07:52
Downgrade
Wabtec rating change  »

Wabtec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SHSP

SharpSpring

$12.84

-0.34 (-2.58%)

07:52
06/24/19
06/24
07:52
06/24/19
07:52
Upgrade
SharpSpring rating change  »

SharpSpring upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$85.58

2.55 (3.07%)

07:50
06/24/19
06/24
07:50
06/24/19
07:50
Downgrade
CarMax rating change  »

CarMax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 24

    Sep

BARZ

5Barz

$0.00

(0.00%)

07:49
06/24/19
06/24
07:49
06/24/19
07:49
Hot Stocks
5Barz signs agreement with Kaynes Technology for Network Extender in India »

5BARz International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAMP

LiveRamp

$51.13

-1.135 (-2.17%)

07:47
06/24/19
06/24
07:47
06/24/19
07:47
Earnings
LiveRamp raises FY20 revenue view to $363M-$377M from $358M-$372M »

Consensus $366.45M.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBIX

Ebix

$47.71

0.48 (1.02%)

07:47
06/24/19
06/24
07:47
06/24/19
07:47
Hot Stocks
Ebix expands A.D.A.M. Health Services business with client wins »

Ebix announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$5.72

-0.07 (-1.21%)

07:46
06/24/19
06/24
07:46
06/24/19
07:46
Downgrade
Oasis Petroleum rating change  »

Oasis Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.